Alcon in the news

Alcon's stock fell 1.82% to CHF 62.74 amid broader market selling pressure, even as it launched new dry eye relief and personalized LASIK products with global expansion plans.

Alcon's stock dipped slightly in afternoon trading, with its Q4 2025 earnings and revenue declining from the prior year, while future earnings are projected to grow.

Alcon Inc. will pay an annual dividend of CHF 0.2800 per share on May 7, 2026.

Alcon's stock price saw a slight decrease, with its quarterly revenue and earnings per share also declining compared to the previous year.

Alcon's stock ranking within the boerse.de-Signale Aktien DACH investment portfolio declined from 234 to 247 on April 24, 2026, according to the BOTSI alph a -Advisor's trend analysis.

An analysis of Alcon's stock performance and valuation metrics shows it to be undervalued by DCF analysis but overvalued by P/E ratio comparison.

Alcon saw strong product-driven growth in late 2025 but faced margin pressure; it plans higher R&D and acquisitions with a positive outlook for 2026.

RBC keeps an 'Outperform' rating on Alcon, expecting positive growth through fiscal year 2026 with updated financial estimates.

Alcon's stock declined midday with lower Q4 earnings and revenue, while analysts forecast a modest dividend increase and 2026 earnings of 2.66 CHF per share.

Alcon's stock fell 3.2% to 62.34 CHF on Thursday, marking it as one of the SMI's biggest losers with significant trading volume.

Alcon expects strong revenue growth and higher dividends in 2025 despite margin pressure from US tariffs and investments, supported by new product launches and positive analyst outlook.

Alcon's stock, despite a recent 15.5% decline over the past year, appears undervalued by 41.7% based on DCF analysis, though its P/E ratio suggests it is overvalued compared to its peers.

Alcon's Q4 revenue reached $2.7 billion with 7% organic growth, led by an 18% increase in eye surgery devices.

Alcon's strong Q4 results and new products boost revenue growth expectations and analyst optimism despite past stock underperformance.

Alcon receives an Outperform rating from RBC and a top-tier AAA ESG score, signaling strong financial health and growth prospects through 2026.

Alcon terminated its merger with Lensar due to regulatory hurdles and FTC opposition despite seeing potential benefits in cataract surgery innovation.

The document summarizes weighted composite ratings and an AAA ESG score for Alcon Inc., reflecting its financial and sustainability performance.

Alcon Inc leads the global eye care market with surgical, pharmaceutical, and vision care offerings, appealing to investors through diversification and growth drivers like aging populations.

Alcon shares experienced a slight increase of 0.9% during midday trading, reaching a daily high of 60.64 CHF.

Alcon is expected to meet its revised 2025 targets and present an accelerated growth outlook soon.